Top News: #Leukemia

Here are the top read news for #Leukemia:


wwwFor high-risk leukemia patients, umbilical cord blood transplant associated with lower risk of relapse:

The study found that such transplants may have advantages beyond offering an alternative stem cell source for patients without a traditional donor match — they seem to perform better against leukemia and the related bone marrow disorder, myelodysplastic syndrome, in patients at high risk of relapse after transplant: Read more

 


satake_norikoHybrid treatment hunts down and kills leukemia cells:

Researchers at UC Davis and Ionis Pharmaceuticals have developed a hybrid treatment that harnesses a monoclonal antibody to deliver antisense DNA to acute lymphoblastic leukemia (ALL) cells and that may lead to less toxic treatments for the disease. The study, published in the journal Molecular Medicine, demonstrated that once delivered, the therapeutic DNA reduced levels of MXD3, a protein that helps cancer cells survive. This novel conjugate therapy showed great promise in animal models, destroying ALL cells while limiting other damage: Read more

 

 


amlVitamin C may boost effectiveness of acute myeloid leukemia treatment:

Combining vitamin C with a demethylating agent in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) may improve the therapy’s ability to combat cancers. At this point, this effect has only been shown in cell lines, and the efficacy in patients can only be confirmed by conducting a rigorous and controlled clinical trial. A pilot clinical trial is underway to investigate the safety and effectiveness of this therapy. If successful, investigators plan to pursue further clinical studies. The investigators urge patience and caution patients to wait for the results of the clinical trial: Read more

 


prwwoxyBCL-2 inhibitor shows promise in AML patients:

Bottom Line: Patients whose acute myelogenous leukemia (AML) had relapsed or was resistant to chemotherapy and those who were deemed unable to tolerate chemotherapy experienced responses to the selective BCL-2 inhibitor venetoclax (Venclexta), with complete remissions in some, according to phase II clinical trial data: Read more

 

 


Cancer Drug PricesFDA slams drug maker for touting unapproved leukemia treatment to docs:

Last June, Celator Pharmaceuticals proudly displayed a large poster touting its experimental Vyxeos medication as an effective salve for treating acute myeloid leukemia. The poster was, in fact, one of countless placards featured prominently on the exhibit floor at the American Society of Clinical Oncology meeting in Chicago, a sort of Woodstock for cancer doctors and eager investors. Despite the numerous displays, however, the Celator poster managed to stick out. That’s because Vyxeos has not yet been approved to treat AML: Read more

.

Advertisements